Tumors are infiltrated by macrophages, T and B-lymphocytes, which may favor tumor development by promoting angiogenesis, growth and invasion. The aim of this study was to investigate the clinical relevance of the relative amount of macrophages (CD68+), T-cells (CD3+) and B-cells (CD20+) at the invasive front of breast carcinomas, and the expression of matrix metalloproteases (MMPs) and their inhibitors (TIMPs) either at the invasive front or at the tumor center. We performed an immunohistochemical study counting CD3, CD20 and CD68 positive cells at the invasive front, in 102 breast carcinomas. Also, tissue sections were stained with MMP-2, -9, -11, -14 and TIMP-2 antibodies, and immunoreactivity location, percentage of reactive area and intensity were determined at the invasive front and at the tumor center. The results showed that an increased CD68 count and CD68/(CD3+CD20) ratio were directly associated with both MMP-11 and TIMP-2 expression by mononuclear inflammatory cells at the tumor center (p = 0.041 and p = 0.025 for CD68 count and p = 0.001 and p = 0.045 for ratio, respectively for MMP-11 and TIMP-2). In addition, a high CD68/(CD3+CD20) ratio (>0.05) was directly associated with a higher probability of shortened relapse-free survival. Multivariate analysis revealed that CD68/(CD3+CD20) ratio was an independent factor associated with distant relapse-free survival (RR: 2.54, CI: (1.23–5.24), p<0.01). Therefore, CD68/(CD3+CD20) ratio at the invasive front could be used as an important prognostic marker.
References
[1]
DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9: 212.
[2]
Johnson JP, Riethmuller G, Schirrmacher V (1989) Tumor immunology: Paul Ehrlich's heritage. Immunol Today 10: S35–37.
[3]
Lin EY, Pollard JW (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90: 2053–2058.
[4]
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867.
[5]
Daniel D, Chiu C, Giraudo E, Inoue M, Mizzen LA, et al. (2005) CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res 65: 2018–2025.
[6]
Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155–1166.
[7]
Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4: 540–550.
[8]
Le Bitoux MA, Stamenkovic I (2008) Tumor-host interactions: the role of inflammation. Histochem Cell Biol 130: 1079–1090.
[9]
Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256: 158–168 discussion 168–172, 259–169.
[10]
Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254–265.
[11]
Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605–612.
[12]
Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, et al. (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67: 10669–10676.
[13]
Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259–267.
[14]
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373–5380.
[15]
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158–5165.
[16]
Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, et al. (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11: R15.
[17]
Denkert C, Loibl S, Noske A, Roller M, Muller BM, et al. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105–113.
[18]
Lofdahl B, Ahlin C, Holmqvist M, Holmberg L, Zhou W, et al. (2012) Inflammatory cells in node-negative breast cancer. Acta Oncol
[19]
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, et al. (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127: 99–108.
[20]
Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, et al. (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132: 545–553.
[21]
Eiro N, Gonzalez LO, Atienza S, Gonzalez-Quintana JM, Beridze N, et al. (2012) Prediction of metastatic breast cancer in non-sentinel lymph nodes based on metalloprotease-1 expression by the sentinel lymph node. Eur J Cancer In press.
[22]
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174.
[23]
Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237–1241.
[24]
Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, et al. (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161: 6845–6852.
[25]
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, et al. (2007) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96: 903–911.
[26]
Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, et al. (2007) Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 97: 957–963.
[27]
Gonzalez LO, Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez JM, et al. (2010) Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology 57: 862–876.
[28]
Del Casar JM, Gonzalez LO, Alvarez E, Junquera S, Marin L, et al. (2009) Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 116: 39–52.
[29]
Eiro N, González L, González LO, Fernandez-Garcia B, Lamelas ML, et al. (2012) Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. Plos One In press.
[30]
Giatromanolaki A, Sivridis E, Koukourakis MI (2004) Tumour angiogenesis: vascular growth and survival. APMIS 112: 431–440.
[31]
Ellis IO, Elston CW (2006) Histologic grade. Breast Pathology. O'Malley FP, Pinder SE ed. Philadelphia, PA: Elsevier. pp. 225–233.
[32]
Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, et al. (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10: 665.
[33]
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309–322.
[34]
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883–899.
[35]
Li Q, Lao X, Pan Q, Ning N, Yet J, et al. (2011) Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 17: 4987–4995.
[36]
Kelly PM, Davison RS, Bliss E, McGee JO (1988) Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer 57: 174–177.
[37]
Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, et al. (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65: 159–163.
[38]
Volodko N, Reiner A, Rudas M, Jakesz R (2004) Tumour-associated macrophages in breast cancer and their prognostic correlations. The Breast 7: 99–105.
[39]
Naukkarinen A, Syrjanen KJ (1990) Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas–correlation with tumour differentiation. J Pathol 160: 217–222.
[40]
Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, et al. (2000) The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 7: 255–262.
[41]
Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, et al. (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132–2141.
[42]
Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11: 91–100.
[43]
Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, et al. (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100: 2757–2765.
[44]
Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P (2003) CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63: 2836–2843.
[45]
Coughlin CM, Vance BA, Grupp SA, Vonderheide RH (2004) RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046–2054.
[46]
DiLillo DJ, Yanaba K, Tedder TF (2010) B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184: 4006–4016.
